Blueprint Medicines (NASDAQ: BPMC) reported Q4 EPS of ($0.75), $0.01 better than the analyst estimate of ($0.76). Revenue for the quarter came in at $7.7 million versus the consensus estimate of $5.87 million.

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.